Drugs that block Janus kinases are showing promise in diseases ranging from myelofibrosis to rheumatoid arthritis, but with the leading agent in line for approval questions remain about their optimal selectivity.
This is a preview of subscription content, log in via an institution to check access.
Rights and permissions
About this article
Cite this article
Dolgin, E. Companies hope for kinase inhibitor JAKpot. Nat Rev Drug Discov 10, 717–718 (2011). https://doi.org/10.1038/nrd3571
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd3571
- Springer Nature Limited
This article is cited by
-
Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition
Nature Medicine (2014)